23andMe—23andMe shared customer genetic data with GSK in $300M deal
· $300.0M
23andMe entered a $300 million deal with pharmaceutical giant GSK to share genetic data from its customer database for drug development research, raising consent and data monetization concerns.
Scoring Impact
| Topic | Direction | Relevance | Contribution |
|---|---|---|---|
| Corporate Transparency | -against | secondary | -0.50 |
| User Privacy | -against | primary | -1.00 |
| Overall incident score = | -0.664 | ||
Score = avg(topic contributions) × significance (high ×1.5) × confidence (0.59)
Evidence (1 signal)
Confirms Partnership Jul 25, 2018 verified
GSK press release announces $300M genetic data sharing agreement with 23andMe
GSK's official press release announced the $300 million agreement with 23andMe to leverage genetic insights from its customer database for novel medicine development.